Sopheon « Terug naar discussie overzicht

Sopheon oktober 2017

23 Posts, Pagina: 1 2 » | Laatste
[verwijderd]
0
Sopheon PLC Issue of Equity

02/10/2017 7:00am
UK Regulatory (RNS & others)

Sopheon (LSE:SPE)
Intraday Stock Chart
Today : Monday 2 October 2017

Click Here for more Sopheon Charts.
TIDMSPE

RNS Number : 3154S

Sopheon PLC

02 October 2017


For immediate release

SOPHEON PLC

("Sopheon" or the "Company")

Issue of Equity

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Management, announces today that it has issued and allotted 10,000 ordinary shares of 20 pence each in the capital of the Company ("Ordinary Shares") in connection with the exercise of share options.

Application has been made for the 10,000 new Ordinary Shares to be admitted to trading on AIM, and dealings are expected to commence on 3 October 2017. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

The total number of Ordinary Shares in issue following Admission will be 7,463,431. The Company does not hold any shares in treasury. Accordingly, the figure of 7,463,431 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Mvg Trinko
[verwijderd]
0
zo is dat gart,mensen die geen soof aandelen hebben,kan je maar beter gelijk geven, tijd voor een pilsie:)
Paiser
0
[verwijderd]
0
Oorzaak is simpelweg dat men graag aandeeltjes wil en denkt dat dat op korte termijn niet goedkoper kan.
Waarom anders instappen op deze prijs?

Ik zit al een tijd te wachten op een doorbraak, inmiddels gaan de ontwikkelingen bij Sopheon gewoon door. Alleen maar positief nieuws.

Het bedrijf is nu grofweg 30 miljoen pond waard.

Eens kijken of de koers nu wel doorzet.....

Klaas

[verwijderd]
0
De directie heeft zelf wel vertrouwen:-))

Sopheon PLC Director/PDMR Shareholding

11/10/2017 10:44am
UK Regulatory (RNS & others)

Sopheon (LSE:SPE)
Intraday Stock Chart
Today : Wednesday 11 October 2017

Click Here for more Sopheon Charts.
TIDMSPE

RNS Number : 3174T

Sopheon PLC

11 October 2017


For Immediate Release

SOPHEON PLC

("Sopheon" or the "Company")

DIRECTOR SHAREHOLDINGS

Sopheon has been notified that certain directors of the Company have purchased shares in the Company.

Barry Mence has purchased 3,000 ordinary shares of 20 pence each in the capital of the Company ("Ordinary Shares") in his Individual Savings Account ("ISA"). Barry Mence's spouse Maria Mence has purchased 2,750 Ordinary Shares in her ISA. The above shares were purchased at a price of GBP3.97 each. In addition, Barry Mence has transferred 2,000 Ordinary Shares from being held in his Self Invested Personal Pension ("SIPP") to his ISA, and he has also transferred 3,000 Ordinary Shares from being held in his SIPP to the ISA of Maria Mence. Barry Mence's total beneficial interest in Ordinary Shares, including those held by his wife, has accordingly increased by 5,750 Ordinary Shares to 1,458,326 Ordinary Shares.

Stuart Silcock has purchased 625 Ordinary Shares in his dealing account. Stuart Silcock's spouse Christine Silcock has purchased 1,250 Ordinary Shares in her dealing account and a further 625 Ordinary Shares in her ISA. The above shares were purchased at a price of GBP3.97 each. In addition, Stuart Silcock has transferred 7,000 Ordinary Shares from being held in his SIPP to his ISA. Stuart Silcock's total beneficial interest in Ordinary Shares, including those of his wife, as well as his interest in Ordinary Shares held in Bare Trust for his grandchildren has accordingly increased by 2,500 Ordinary Shares to 279,627 Ordinary Shares.

Trinko
[verwijderd]
0
mogge, dit is de 3de keer dat ze deze aantallen kopen,bestuurders + famillie, lijkt niet veel,maar dat 3keer doen ,kom je toch aan flinke aantallen,ze gaan echt niet kopen,als ze weten dat de nabije toekomst er slecht uit gaat zien, de voorzitter en zn bestuurders weten, natuurlijk veel meer dan ons, wat er allemaal nog komen gaat.
Arie de Beuker
0
Ik weet bijna zeker dat ze dividend gaan uitkeren. Let maar op. Het gaat gewoon goed met Sopheon anders kopen ze echt niet voor hun oude dag.

Gr
Arie de Beuker
Gartje
0
Dividend mogen ze in hun bolle r..t stoppen, laten ze maar zorgen voor een overname prijs van 8 tot 10 euro;-))))
[verwijderd]
0
mogge,ja een overname ben ik ook voor, goed bod en het boek soof sluiten, we kunnen wel wachten tot sint juttemus,maar we worden ook een dagje ouder he,
en die dividend zit ik ook niet op te wachten.
Harry Nik
0
Hallootjes...
Zit niet echt vaart in he..lage volumes..jojo een beetje rond de 4 euro..
Wordt het nog wat denkt iemand?
Bertus S
1
Sopheon Awarded Funding for European Research Projects

Funding recognizes Sopheon’s ongoing contribution to research on market disruptors such as Internet of Things, real-time decision support, and advanced analytics embedded into business process

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, today announced the award of European funding for innovative research in the framework of the EUREKA/ITEA research program alongside a consortium of project partners. The funding is for two different projects, Medolution and PARTNER.

Both research projects focus on developing innovative and intelligent methods and software for real time handling of massive volumes of data across complex scenarios, with emphasis on the healthcare industry. Sopheon’s contribution to these projects focuses on applying the data-driven decision support capabilities of our Accolade® software. Sopheon benefits in return from the collaboration with project partners - research institutes and leading software companies such as Philips Healthcare, Atos/Bull, Siemens Healthcare, Barco, IMEC, KPN and NXP Semiconductors – to develop breakthrough capabilities for commercial application in our software.

In the current digital age, organizations are looking for technologies that allow them to handle unprecedented amounts of information, with speed. This information is drawn from a very incoherent landscape of IT systems and sources, within as well as beyond the physical boundaries of the enterprise. The data to be handled comes from many different sources – structured and unstructured data; metadata from sensor data, images, video – and is reused in the context of big data analysis, internet of things (IoT) techniques, cloud services, etc.

The Accolade software is able to interpret all of this data in real time, irrespective of source or format, based on rules and criteria defined by domain experts and within predefined best practice protocols that are managed by the Accolade system.

Huub Rutten, VP Research and Application Development at Sopheon, stated:

“For Sopheon the research is very applicable to our core enterprise innovation management clients and future product strategy. Our work in these projects positions us to develop relationships with some of the leading companies in the world for commercial leverage, and to develop innovative strategic technologies and applications for our target markets. Further, our research discoveries also have the potential to open new market segments for our application.”
This award brings to a total of five the number of research grants awarded to Sopheon since 2009.

Sopheon® and Accolade® are trademarks of Sopheon

www.sopheon.com/sopheon-awarded-fundi...

Bertus S.
[verwijderd]
0
Dat is een mooie erkenning wederom.
Ze blijven zich erg goed ontwikkelen.

Healthcare is een grote markt, Sopheon's exposure daarin wordt alsmaar groter.

Dat moet zijn vruchten gaan afwerpen, dat kan niet anders.

Klaas
[verwijderd]
0
het soof gebouw moet onderhand,helemaal propvol zitten met gewonnen prijzen,nu de koers nog.
23 Posts, Pagina: 1 2 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 874,79 +8,28 +0,96% 23 apr
AMX 934,43 +5,75 +0,62% 23 apr
ASCX 1.204,05 +15,50 +1,30% 23 apr
BEL 20 3.890,71 +27,45 +0,71% 23 apr
Germany40^ 18.161,70 +24,05 +0,13% 23 apr
US30^ 38.504,96 0,00 0,00% 23 apr
US500^ 5.069,70 0,00 0,00% 23 apr
Nasd100^ 17.481,67 0,00 0,00% 23 apr
Japan225^ 37.938,71 0,00 0,00% 23 apr
WTI 83,30 0,00 0,00% 23 apr
Brent 88,29 0,00 0,00% 23 apr
EUR/USD 1,0702 +0,0050 +0,47% 02:06
BTC/USD 66.251,65 -313,87 -0,47% 01:15
Gold spot 2.322,55 +0,53 +0,02% 02:06
#/^ Index indications calculated real time, zie disclaimer
HOGE RENDEMENTEN OP DE IEX-MODELPORTEFEUILLES > WORD NU ABONNEE EN PROFITEER VAN MAAR LIEFST 67% KORTING!

Stijgers & Dalers

Stijgers Laatst +/- % tijd
PROSUS 30,890 +1,050 +3,52% 23 apr
ASMI 531,600 +16,200 +3,14% 23 apr
ASML 834,300 +21,100 +2,59% 23 apr
Dalers Laatst +/- % tijd
RANDSTAD NV 45,000 -3,500 -7,22% 23 apr
Akzo Nobel 62,280 -4,640 -6,93% 23 apr
ArcelorMittal 23,470 -0,640 -2,65% 23 apr

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront